Summary by Moomoo AI
Biora Therapeutics, Inc. has filed a prospectus supplement on April 2, 2024, which updates and amends certain information from the original prospectus dated June 30, 2021. The supplement pertains to the offering of 1,295,546 shares of common stock, including shares issuable upon the exercise of warrants. The company has entered into a Warrant Amendment Agreement on March 31, 2024, with an institutional investor to amend the exercise price of warrants to purchase up to 80,000 shares of common stock. The exercise price of these warrants has been reduced from $8.22 to $1.10 per share, following a reverse stock split in January 2023. The amended warrants will not be exercisable until stockholder approval is obtained, and their expiration has been extended to five years post-approval. The last reported sale price of Biora Therapeutics' common stock on the Nasdaq Global Market was $1.10 per share as of March 28, 2024.